Article: Immune Response Cuts Staff To Focus On Remune; CEO Resigns.

Staff Writer

The Immune Response Corp. said Monday it is reducing its staff in an effort to cut costs by $1.8 million per quarter while narrowing its focus to its most advanced product, the HIV therapeutic vaccine, Remune.

The Carlsbad, Calif.-based company also said that following a meeting Friday of its board, CEO and President Dennis Carlo resigned and the company appointed Ronald Moss as president. Carlo had been CEO since 1994, while Moss, who joined the company as medical director in 1994, had served in other positions before being named vice president, medical and scientific affairs in January 2000.

The company had $1.1 million in cash as ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!